Key clinical point: Overall health-related quality of life (HRQoL) was maintained with the addition of apalutamide to androgen deprivation therapy (ADT) in patients with nonmetastatic castration-resistant prostate cancer (CRPC).
Major finding: The change in Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score significantly favored apalutamide vs placebo at treatment cycles 21 ( P = .0138) and 25 ( P = .0009). No difference was seen in the median time to deterioration in scores for FACT-P and subscales.
Study details: HRQoL analysis of phase 3, randomized SPARTAN trial of patients with nmCRPC who were randomly assigned to receive apalutamide or placebo. All patients continued ADT.
Disclosures: This study was funded by Janssen Research & Development. The authors received consulting/personal/advisory/speaker fees, honoraria, royalties, research funding, lectureship fees, and/or travel expenses from various sources. Some authors reported being an investigator in clinical trials and stock ownership in pharmaceutical companies.
Source: Oudard S et al. Eur Urol Focus. 2021 Aug 31. doi: 10.1016/j.euf.2021.08.005 .